Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses disease-specific prognostic factors of acute myeloid leukemia (AML). Measurable residual disease (MRD) is an on-treatment outcome parameter but there are also parameters known at diagnosis; previously this was limited to cytogenetics. Certain cytogenetically-defined AMLs are associated with good prognosis, such as core-binding factor AML, whereas others, such as EVI-1 overexpression, are associated with poor outcome. This has implications for treatment choice such as whether a patient should receive an allogeneic stem cell transplantation. More recently, other mutations associated with leukemogenesis and prognosis have been detected using next-generation sequencing (NGS). Taken together, there are now several mutations that are taken into account in risk stratification of AML.
Recorded at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany.